On Friday, UroGen Pharma Ltd (NASDAQ: URGN) was -4.55% drop from the session before settling in for the closing price of $18.59. A 52-week range for URGN has been $3.42 – $21.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 10.39% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -0.79%. With a float of $39.74 million, this company’s outstanding shares have now reached $46.20 million.
In an organization with 235 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 89.68%, operating margin of -117.51%, and the pretax margin is -147.23%.
UroGen Pharma Ltd (URGN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward UroGen Pharma Ltd stocks. The insider ownership of UroGen Pharma Ltd is 14.11%, while institutional ownership is 105.31%. The most recent insider transaction that took place on Jul 28 ’25, was worth 143,971. In this transaction General Counsel of this company sold 7,522 shares at a rate of $19.14, taking the stock ownership to the 41,492 shares. Before that another transaction happened on Jul 28 ’25, when Company’s Chief Medical Officer sold 5,149 for $19.14, making the entire transaction worth $98,552. This insider now owns 158,229 shares in total.
UroGen Pharma Ltd (URGN) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.55 earnings per share (EPS) during the time that was better than consensus figure (set at -0.82) by 0.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.79% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
You can see what UroGen Pharma Ltd (URGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.32, a number that is poised to hit -0.63 in the next quarter and is forecasted to reach -0.82 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.39 million. That was inferior than the volume of 1.59 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 41.84%.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 81.42%, which indicates a significant increase from 42.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.31 in the past 14 days, which was higher than the 0.99 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.65, while its 200-day Moving Average is $11.45. However, in the short run, UroGen Pharma Ltd’s stock first resistance to watch stands at $18.66. Second resistance stands at $19.57. The third major resistance level sits at $20.18. If the price goes on to break the first support level at $17.14, it is likely to go to the next support level at $16.54. The third support level lies at $15.62 if the price breaches the second support level.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
There are 46,201K outstanding shares of the company, which has a market capitalization of 820.96 million. As of now, sales total 90,400 K while income totals -126,870 K. Its latest quarter income was 20,250 K while its last quarter net income were -43,840 K.
